Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, discussions focused on data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
What Do Our 2021 Speakers Have To Say?
"This conference brings together thought leaders and experts across disciplines to tackle the frontiers of anti-infective drug development in the quest for superior clinical outcomes"
Cara Cassino, Executive Vice President of R&D & Chief Medical Officer, ContraFect
"We are excited to participate in an infectious disease-focused conference with an emphasis on drug development"
Dave Ousterout, Chief Scientific Officer, Locus Biosciences
"I look for to receiving an update on progress on development of anti-bacterials, especially in less traditional areas"
Marc Navre, Chief Executive Officer & Chief Scientific Officer, Facile Therapeutics
"I look forward to sharing experience in drug development for rare pathogen and engaging in dialog around opportunities to support innovative design, regulatory review and product use"
David Altarac, Chief Medical Officer, Entasis Therapeutics
"I look forward to networking with other leaders, updates from other companies on pipeline progress and strategy, progress on commercial and pull mechanisms"
David Powell, Chief Scientific Officer, Summit Therapeutics
"This digital conference will increase public and industry awareness about the global threat of resistant bacterial infections and the emerging therapies to address unmet medical needs"
Mike Gordeev, Chief Scientific Officer, MicuRx Pharmaceuticals